Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.

被引：7
|
作者：
Antoniotti, Carlotta
Cremolini, Chiara
Loupakis, Fotios
Bergamo, Francesca
Grande, Roberta
Tonini, Giuseppe
Garattini, Silvio Ken
Masi, Gianluca
Battaglin, Francesca
Lucchesi, Sara
Salvatore, Lisa
Corsi, Domenico C.
Di Fabio, Francesca
Banzi, Maria
Sensi, Elisa
Tomcikova, Daniela
Fontanini, Gabriell
Zagonel, Vittorina
Boni, Luca
Falcone, Alfredo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3543
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO
    Cremolini, C.
    Antoniotti, C.
    Loupakis, F.
    Bergamo, F.
    Ferrari, L.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Solda, C.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Garattini, S. K.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Ruman, L.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Delliponti, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Grande, R.
    Tonini, G.
    Silvio, K. Garattini
    Masi, G.
    Battaglin, F.
    Lucchesi, S.
    Salvatore, L.
    Corsi, D.
    Di Fabio, F.
    Banzi, M.
    Moretto, R.
    Sensi, E.
    Rossini, D.
    Tomcikova, D.
    Fontanini, G.
    Zagonel, V.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 121 - 122
  • [4] Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
    Cremolini, Chiara
    Antoniotti, Carlotta
    Lonardi, Sara
    Aprile, Giuseppe
    Bergamo, Francesca
    Masi, Gianluca
    Grande, Roberta
    Tonini, Giuseppe
    Mescoli, Claudia
    Cardellino, Giovanni Gerardo
    Coltelli, Luigi
    Salvatore, Lisa
    Corsi, Domenico Cristiano
    Lupi, Cristiana
    Gemma, Donatello
    Ronzoni, Monica
    Dell'Aquila, Emanuela
    Marmorino, Federica
    Di Fabio, Francesca
    Mancini, Maria Laura
    Marcucci, Lorenzo
    Fontanini, Gabriella
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    [J]. JAMA ONCOLOGY, 2018, 4 (04) : 529 - 536
  • [5] Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Salvatore, Lisa
    Lonardi, Sara
    Battaglin, Francesca
    Gamucci, Teresa
    Grande, Roberta
    Di Fabio, Francesca
    Liimpe, Fabiola Lorena Rojas
    Ferrari, Laura
    Casagrande, Mariaelena
    Lucchesi, Sara
    Tonini, Giuseppe
    Banzi, Maria
    Valsuani, Chiara
    Corsi, Domenico C.
    Fontanini, Gabriella
    Tomcikova, Daniela
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
    Conca, V.
    Antoniotti, C.
    Bergamo, F.
    Pietrantonio, F.
    Rossini, D.
    Scartozzi, M.
    Perissinotto, E.
    Leone, A.
    Pusceddu, V.
    Borelli, B.
    Cavanna, L.
    Latiano, T.
    Santini, D.
    Masi, G.
    Salvatore, L.
    Frassineti, G.
    Leone, F.
    Tamberi, S.
    Boni, L.
    Cremolini, C.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S173 - S173
  • [7] Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
    Conca, Veronica
    Antoniotti, Carlotta
    Bergamo, Francesca
    Pietrantonio, Filippo
    Rossini, Daniele
    Scartozzi, Mario
    Perissinotto, Eleonora
    Leone, Alberto Giovanni
    Valeria, Pusceddu
    Borelli, Beatrice
    Cavanna, Luigi
    Latiano, Tiziana Pia
    Santini, Daniele
    Masi, Gianluca
    Salvatore, Lisa
    Frassineti, Luca
    Leone, Francesco
    Tamberi, Stefano
    Boni, Luca
    Cremolini, Chiara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO
    Marmorino, F.
    Cremolini, C.
    Bergamo, F.
    Pella, N.
    Antoniotti, C.
    Rossini, D.
    Dell'Aquila, E.
    Masi, G.
    Salvatore, L.
    Loupakis, F.
    Marcucci, L.
    Gemma, D.
    Cardellino, G.
    Borelli, B.
    Ricci, V.
    Delfanti, S.
    Mori, E.
    Tonini, G.
    Lonardi, S.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [9] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
    Falcone, A.
    Cremolini, C.
    Loupakis, F.
    Lonardi, S.
    Casagrande, M. E.
    Murgioni, S.
    Salvatore, L.
    Masi, G.
    Fanotto, V.
    Granetto, C.
    Marmorino, F.
    Ginocchi, L.
    Ziampiri, S.
    Grande, R.
    Tonini, G.
    Delfanti, S.
    Di Donato, S.
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
    Bennouna, J.
    Hiret, S.
    Borg, C.
    Bertaut, A.
    Bouche, O.
    Deplanque, G.
    Francois, E.
    Conroy, T.
    Ghiringhelli, F.
    des Guetz, G.
    Seitz, J-F.
    Artru, P.
    Stanbury, T.
    Charpentier, S.
    Denis, M.
    Adenis, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345